View study design
The safety and efficacy of COBENFY were assessed in 3, randomized, double-blind, placebo-controlled studies. EMERGENT-2 (N=252) and EMERGENT-3 (N=256) were phase 3 trials and EMERGENT-1 (N=182) was a phase 2 trial. The primary end point was change in PANSS total score from baseline at Week 5.5,6 See additional study design details.